ArticleAIDS research and therapy2025

Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide.

Karam Mounzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.